Today: 9 April 2026
Subscribe
Browse Category

NASDAQ:FOLD 14 December 2025 - 22 December 2025

BioMarin (BMRN) Stock News Today: Amicus Acquisition Fallout, BMN 349 Cut, and Fresh Wall Street Price Targets (Dec. 22, 2025)

BioMarin (BMRN) Stock News Today: Amicus Acquisition Fallout, BMN 349 Cut, and Fresh Wall Street Price Targets (Dec. 22, 2025)

BioMarin shares fell 3.5% to $58.98 on Dec. 22 after analysts weighed in on its $4.8 billion Amicus Therapeutics acquisition and the company confirmed it ended development of BMN 349. Truist Securities raised its price target to $100, citing strategic fit, while other analysts questioned the deal’s impact on growth and balance sheet risk.
22 December 2025
··
Amicus Therapeutics (FOLD) Stock Today: BioMarin’s $14.50 Cash Buyout, Analyst Downgrades, and What Investors Watch Next (Dec. 22, 2025)

Amicus Therapeutics (FOLD) Stock Today: BioMarin’s $14.50 Cash Buyout, Analyst Downgrades, and What Investors Watch Next (Dec. 22, 2025)

BioMarin agreed to acquire Amicus Therapeutics for $14.50 per share in cash, valuing Amicus at $4.8 billion. FOLD traded near $14.22 on December 22, reflecting market expectations for deal completion and timing. The transaction is expected to close in Q2 2026, pending regulatory and shareholder approvals. Either party may terminate if not closed by June 19, 2026, with a $175 million breakup fee.
22 December 2025
··
Amicus Therapeutics (FOLD) Stock News Today: BioMarin’s $14.50 Buyout, Fresh Analyst Forecasts, and Key Dates to Watch (Dec. 22, 2025)

Amicus Therapeutics (FOLD) Stock News Today: BioMarin’s $14.50 Buyout, Fresh Analyst Forecasts, and Key Dates to Watch (Dec. 22, 2025)

Amicus Therapeutics shares traded near $14.18 on Dec. 22, 2025, following BioMarin Pharmaceutical’s agreement to acquire the company for $14.50 per share in cash. Both boards have approved the $4.8 billion deal, with closing expected in Q2 2026 pending regulatory and shareholder approval. The narrow price spread reflects typical merger-arbitrage dynamics. Citigroup reaffirmed a Neutral rating and set a $14.50 target.
22 December 2025
···
Amicus Therapeutics (FOLD) Stock on Dec. 22, 2025: BioMarin’s $14.50 Buyout, Latest News, Analyst Forecasts, and What’s Next

Amicus Therapeutics (FOLD) Stock on Dec. 22, 2025: BioMarin’s $14.50 Buyout, Latest News, Analyst Forecasts, and What’s Next

BioMarin Pharmaceutical agreed to acquire Amicus Therapeutics for $14.50 per share in cash, valuing Amicus at about $4.8 billion. Amicus shares traded at $14.18 on Dec. 22, reflecting market focus on deal completion. TD Cowen downgraded Amicus to Hold, setting a $14.50 target. The deal is expected to close in Q2 2026, pending approvals.
22 December 2025
··
Amicus Therapeutics (FOLD) Stock Week Ahead: $14.50 BioMarin Buyout Puts the Deal Spread—and New Filings—Front and Center (Dec. 22–26, 2025)

Amicus Therapeutics (FOLD) Stock Week Ahead: $14.50 BioMarin Buyout Puts the Deal Spread—and New Filings—Front and Center (Dec. 22–26, 2025)

BioMarin Pharmaceutical agreed Friday to acquire Amicus Therapeutics for $14.50 per share in cash, valuing the company at $4.8 billion. FOLD shares closed near $14.18 after jumping 30% on the news. The deal is expected to close in Q2 2026, pending shareholder and regulatory approvals. Amicus disclosed a $175 million breakup fee and a June 19, 2026 outside date.
22 December 2025
····
BioMarin (BMRN) Stock Jumps on $4.8 Billion Amicus Deal: Latest News, Forecasts and Analyst Outlook for Dec. 21, 2025

BioMarin (BMRN) Stock Jumps on $4.8 Billion Amicus Deal: Latest News, Forecasts and Analyst Outlook for Dec. 21, 2025

BioMarin shares jumped 17.7% to $61.15 on December 19 after announcing a $4.8 billion all-cash deal to acquire Amicus Therapeutics for $14.50 per share, a 33% premium. Trading volume hit 18.5 million shares. The acquisition, expected to close in Q2 2026, adds two marketed rare-disease drugs and a late-stage asset to BioMarin’s portfolio.
21 December 2025
···
Amicus Therapeutics Stock (FOLD) News: BioMarin’s $14.50 Cash Buyout, Deal Timeline, and the Latest Forecasts (Dec. 21, 2025)

Amicus Therapeutics Stock (FOLD) News: BioMarin’s $14.50 Cash Buyout, Deal Timeline, and the Latest Forecasts (Dec. 21, 2025)

BioMarin Pharmaceutical will acquire Amicus Therapeutics for $14.50 per share in cash, valuing the deal at about $4.8 billion. Amicus stock closed at $14.18 on December 19, up 30% in a day and near the offer price. The deal is expected to close in Q2 2026, pending regulatory and shareholder approval. Amicus resolved key Galafold patent litigation ahead of the announcement.
21 December 2025
···
Biotechnology Stocks Week Ahead (Dec. 22–26, 2025): BioMarin–Amicus Deal, Cytokinetics FDA Win, IPO Filings, and Drug-Price Policy Risks

Biotechnology Stocks Week Ahead (Dec. 22–26, 2025): BioMarin–Amicus Deal, Cytokinetics FDA Win, IPO Filings, and Drug-Price Policy Risks

BioMarin agreed to acquire Amicus Therapeutics for $4.8 billion on Dec. 19, paying a 33% premium and adding two rare-disease drugs with $599 million in combined annual sales. The deal, plus an FDA approval for Cytokinetics and new IPO filings, drove biotech stocks higher ahead of the Christmas-shortened trading week. U.S. markets will close early Dec. 24 and remain shut Dec. 25.
21 December 2025
·····
Amicus Therapeutics (FOLD) Stock Today: BioMarin’s $14.50 Cash Buyout, Latest News, Analyst Forecasts, and What Comes Next (Dec. 21, 2025)

Amicus Therapeutics (FOLD) Stock Today: BioMarin’s $14.50 Cash Buyout, Latest News, Analyst Forecasts, and What Comes Next (Dec. 21, 2025)

BioMarin Pharmaceutical agreed to acquire Amicus Therapeutics for $14.50 per share in cash, valuing Amicus at $4.8 billion. Amicus closed at $14.20 on Dec. 19, just below the buyout price. The deal, approved by both boards, is expected to close in Q2 2026 pending regulatory and shareholder approval. BioMarin plans to fund the purchase with cash and about $3.7 billion in new debt.
21 December 2025
··
Amicus Therapeutics (FOLD) Stock Jumps on BioMarin’s $4.8B Buyout: Latest News, Forecasts, and Deal Analysis as of Dec. 20, 2025

Amicus Therapeutics (FOLD) Stock Jumps on BioMarin’s $4.8B Buyout: Latest News, Forecasts, and Deal Analysis as of Dec. 20, 2025

BioMarin Pharmaceutical will acquire Amicus Therapeutics in an all-cash deal valued at $4.8 billion, offering $14.50 per share. Amicus stock surged about 30% after the Dec. 19 announcement, trading near $14.18 as of Dec. 20. The deal awaits regulatory and shareholder approval, with closing expected in Q2 2026. Trading volume spiked as investors focused on merger risk and timing.
21 December 2025
··
Amicus Therapeutics (FOLD) Stock Today: BioMarin’s $4.8B Cash Buyout at $14.50 Resets the Outlook (Dec. 20, 2025)

Amicus Therapeutics (FOLD) Stock Today: BioMarin’s $4.8B Cash Buyout at $14.50 Resets the Outlook (Dec. 20, 2025)

BioMarin Pharmaceutical will acquire Amicus Therapeutics for $14.50 per share in cash, valuing the deal at about $4.8 billion. Amicus shares closed at $14.18 on December 19, reflecting a small merger spread tied to regulatory and deal-closing risks. Both boards approved the agreement. Closing is targeted for Q2 2026, pending shareholder and antitrust approvals.
20 December 2025
···
BioMarin (BMRN) Stock Surges on $4.8B Amicus Deal: Latest News, Analyst Forecasts, and What to Watch Next (Dec. 20, 2025)

BioMarin (BMRN) Stock Surges on $4.8B Amicus Deal: Latest News, Analyst Forecasts, and What to Watch Next (Dec. 20, 2025)

BioMarin shares jumped 17.7% to $61.15 Friday after announcing a $4.8 billion all-cash deal to acquire Amicus Therapeutics at $14.50 per share. The acquisition adds two marketed rare-disease drugs and a Phase 3 asset, and resolves U.S. patent litigation over Galafold, delaying generic entry to 2037. BioMarin expects the deal to close in Q2 2026 and be accretive to earnings within a year.
20 December 2025
····
Amicus Therapeutics Stock (FOLD) Surges as BioMarin Agrees to Buy the Rare-Disease Biotech for $4.8 Billion

Amicus Therapeutics Stock (FOLD) Surges as BioMarin Agrees to Buy the Rare-Disease Biotech for $4.8 Billion

BioMarin Pharmaceutical agreed to acquire Amicus Therapeutics in an all-cash deal valued at about $4.8 billion, offering $14.50 per share. Amicus stock jumped roughly 30% to $14.18 on heavy volume, trading just below the bid as investors assess deal closure risks. Both boards approved the transaction, with closing targeted for Q2 2026 pending shareholder and regulatory approvals.
20 December 2025
·····
Amicus Therapeutics Stock (FOLD) Surges After $4.8B BioMarin Buyout: $14.50 Offer, Deal Timeline, Analyst Outlook (Dec. 20, 2025)

Amicus Therapeutics Stock (FOLD) Surges After $4.8B BioMarin Buyout: $14.50 Offer, Deal Timeline, Analyst Outlook (Dec. 20, 2025)

BioMarin Pharmaceutical announced a $14.50-per-share all-cash deal to acquire Amicus Therapeutics, valuing the company at about $4.8 billion. Amicus shares jumped 30% to $14.18 following the news, trading just below the offer price. The deal is expected to close in the second quarter of 2026, pending regulatory and shareholder approval.
20 December 2025
··
Amicus Therapeutics (FOLD) Stock After Hours Dec. 19, 2025: BioMarin’s $14.50 Cash Buyout and What to Know Before the Next Market Open

Amicus Therapeutics (FOLD) Stock After Hours Dec. 19, 2025: BioMarin’s $14.50 Cash Buyout and What to Know Before the Next Market Open

BioMarin Pharmaceutical agreed to acquire Amicus Therapeutics for $14.50 per share in cash, valuing the deal at about $4.8 billion. Amicus stock jumped roughly 30% Friday, closing near $14.18. Both boards approved the transaction, expected to close in Q2 2026. The offer is not subject to financing conditions.
20 December 2025
··
BioMarin to Acquire Amicus Therapeutics for $4.8 Billion in All‑Cash Deal, Expanding Rare Disease Drug Portfolio

BioMarin to Acquire Amicus Therapeutics for $4.8 Billion in All‑Cash Deal, Expanding Rare Disease Drug Portfolio

BioMarin Pharmaceutical will acquire Amicus Therapeutics in an all-cash deal valued at about $4.8 billion, paying $14.50 per share—a 33% premium to Amicus’ prior close. The transaction, approved by both boards, is expected to close in Q2 2026 pending shareholder and regulatory approvals. BioMarin will fund the deal with cash and $3.7 billion in debt financing. The acquisition adds two rare-disease drugs and a Phase 3 pipeline asset.
19 December 2025
····
Amicus Therapeutics (FOLD) Stock News Today: DMX-200 Trial Milestone, 52-Week High Momentum, and Analyst Forecasts (Dec. 15, 2025)

Amicus Therapeutics (FOLD) Stock News Today: DMX-200 Trial Milestone, 52-Week High Momentum, and Analyst Forecasts (Dec. 15, 2025)

Amicus Therapeutics shares traded at $10.93 intraday Monday after opening at $10.55, with the session range reaching $11.11. The company reported Q3 GAAP net income of $17.3 million on $169.1 million revenue and reaffirmed 2025 guidance. Recent attention follows a Phase 3 milestone in its kidney-disease program and expanding Pompe franchise launches.
15 December 2025
··
Amicus Therapeutics (FOLD) Stock News, Forecasts and Analyst Outlook on Dec. 14, 2025: What’s Driving the Rally?

Amicus Therapeutics (FOLD) Stock News, Forecasts and Analyst Outlook on Dec. 14, 2025: What’s Driving the Rally?

Amicus Therapeutics shares closed at $10.55 Friday, up 6.6% after hitting a 52-week high of $10.85. Renewed bullish analyst coverage, including a Zacks “strong buy” and a mean price target of $15.90, followed the move. The company’s profitability trajectory and recent earnings have drawn increased attention from investors.
14 December 2025
··

Stock Market Today

  • iShares Russell 1000 Value ETF (IWD) Sees $754.6M Inflows, Boosting Holdings in BRK.B, CAT, RTX
    April 9, 2026, 11:43 AM EDT. The iShares Russell 1000 Value ETF (IWD) recorded a $754.6 million inflow this week, marking a 1.0% rise in outstanding units. The ETF's major components-Berkshire Hathaway Inc (BRK.B), Caterpillar Inc (CAT), and RTX Corp (RTX)-posted gains of 0.9%, 0.8%, and 0.1% respectively. IWD's share price currently trades near its 52-week high, at $222.04 versus a high of $226.39. Exchange-traded funds (ETFs) allow investors to buy units that represent a basket of equities; substantial inflows signal increased underlying stock purchases, potentially impacting prices of these shares. Investors watch such inflows closely as indicators of market interest shifts.

Latest article

Salesforce Stock Hits Fresh 52-Week Low Despite AI Growth and $50 Billion Buyback

Salesforce Stock Hits Fresh 52-Week Low Despite AI Growth and $50 Billion Buyback

9 April 2026
Salesforce shares hit a new 52-week low Thursday, dropping 3.7% to $169.76 despite reporting 12% revenue growth and strong demand for its AI products. The broader software sector continued to slide, with the S&P 500 software and services index down about $1 trillion since January. Salesforce raised its buyback authorization to $50 billion and increased its dividend to 44 cents a share.
ServiceNow Stock Hits Fresh 52-Week Low as Analysts Cut Targets Ahead of Earnings

ServiceNow Stock Hits Fresh 52-Week Low as Analysts Cut Targets Ahead of Earnings

9 April 2026
ServiceNow shares dropped 5.1% to $92.45 by 10:20 a.m. EDT Thursday, hitting a new 52-week low after analysts at Stifel, BTIG, and Goldman Sachs cut price targets citing weak federal spending and limited 2026 growth. The company announced it will integrate AI, data, security, and governance into all products ahead of first-quarter results due April 22.
SoFi Technologies Stock Slips as Wall Street Cuts Targets Ahead of Q1 Earnings

SoFi Technologies Stock Slips as Wall Street Cuts Targets Ahead of Q1 Earnings

9 April 2026
SoFi Technologies shares fell 1.9% to $16.18 Thursday after KBW and Wells Fargo cut price targets ahead of first-quarter results due April 29. The moves follow Muddy Waters’ short position and claims of accounting issues, which SoFi denies. Affirm and LendingClub also traded lower. Barclays and other banks have trimmed targets as concerns mount over credit quality and sector valuations.
Tesla revives cheaper EV bet with compact SUV plan in China after sales strain

Tesla revives cheaper EV bet with compact SUV plan in China after sales strain

9 April 2026
Tesla is developing a smaller, cheaper electric SUV to be built first in Shanghai, sources said. The new model would cost less than the Model 3 and be smaller than the Model Y. Tesla produced 408,386 vehicles but delivered only 358,023 in Q1, as U.S. demand weakened and competition increased. Shares fell 0.8% Thursday.
Grab Holdings Bets on AI as Group Ride Tool Targets 40% Lower Fares

Grab Holdings Bets on AI as Group Ride Tool Targets 40% Lower Fares

9 April 2026
Grab Holdings launched 13 new AI-powered products in Jakarta, including a “Group Ride” feature that can cut fares by up to 40% for shared routes. CEO Anthony Tan said the tools aim to offset rising fuel costs and support demand as households tighten spending. The company’s 2026 revenue and profit forecasts remain below analyst expectations. Grab’s $600 million deal to buy Foodpanda Taiwan is pending regulatory approval.
Go toTop